<DOC>
	<DOCNO>NCT01690507</DOCNO>
	<brief_summary>Demethylating agent decitabine enhances immunogenicity leukemia cell induce expression cancer testis antigen ( CTAs ) , MHC class I II molecule , costimulatory molecule adhesion molecule . The leukemias cell treat decitabine become sensitive follow adoptive T cell therapy .</brief_summary>
	<brief_title>Decitabine Combining Modified CAG Followed HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion Elderly Patients With Acute Myeloid Leukemia ( AMLï¼‰</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Aclacinomycins</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>PATIENT Must diagnosis MDSRAEB AML base 2008 World Health Organization ( WHO ) classification myeloid malignancy Must life expectancy &gt; = 3 month Must ability observe efficacy event Must accompany therapy ( include steroid ) Patient must ability understand willingness provide write informed consent prior participation study relate procedure perform Must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 3 Must haploidentical donor DONOR Must sign standard inform consent form ; sufficient cryopreserved cell remain previous donation , additional donation consent require Both men woman member race ethnic group eligible trial PATIENT Must advance malignant hepatic tumor Must receive form chemotherapy cell infusion treatment protocol Must receive investigational agent within 14 day first dose study drug Must uncontrolled intercurrent illness include ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement Must pregnant breastfeeding ; pregnant woman exclude study decitabine Category D agent potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother decitabine , breastfeed discontinue mother treated decitabine ; potential risk may also apply agent use study Must history allergic reaction attribute compound similar chemical biologic composition decitabine agent use study Must know suspected hypersensitivity decitabine Must human immunodeficiency virus ( HIV ) positive combination antiretroviral therapy ; patient ineligible potential pharmacokinetic interaction decitabine ; addition , patient increase risk lethal infection treat marrowsuppressive therapy ; appropriate study undertake patient receive combination antiretroviral therapy indicate DONOR Must underlying condition would contraindicate apheresis Must pregnant</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>demethylating agent</keyword>
	<keyword>immunogenicity</keyword>
</DOC>